Qinghu Ren1, Liying Zhang2, Rachel Ruoff3,4, Susan Ha3,4, Jinhua Wang5,6, Shilpa Jain1, Victor Reuter2, William Gerald2, Dilip D Giri2, Jonathan Melamed1, Michael J Garabedian3,7,6, Peng Lee1,3,8,6, Susan K Logan3,4,6. 1. Department of Pathology, New York University School of Medicine, New York, NY. 2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Urology, New York University School of Medicine, New York, NY. 4. Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY. 5. Department of Center for Health Informatics and Bioinformatics, New York University Langone Medical Center, New York, NY. 6. Department of New York University Cancer Institute, New York, NY. 7. Department of Microbiology, New York University School of Medicine, New York, NY. 8. Department of New York Harbor Healthcare System, New York, NY.
Abstract
BACKGROUND: Androgen receptor (AR) expression in breast cancers may serve as a prognostic and predictive marker. We examined the expression pattern of AR and its phosphorylated forms, Ser-213 (AR-Ser[P]-213) and Ser-650 (AR-Ser[P]-650), in breast cancer and evaluated their association with clinicopathological parameters. METHODS: Immunohistochemistry was performed on primary and distant metastatic breast cancers and benign breast tissue using antibodies against AR, AR-Ser(P)-213, and AR-Ser(P)-650. The levels of cytoplasmic and nuclear expression were scored semiquantitatively using a histoscore. RESULTS: Nuclear staining of AR was observed in all benign breast tissue and 67% of cancer cases. Nuclear and cytoplasmic AR-Ser(P)-213 was increased in breast cancers 2-fold (P = .0014) and 1.7-fold (P = .05), respectively, compared with benign controls, whereas nuclear and cytoplasmic AR-Ser(P)-650 expression was decreased in tumors by 1.9-fold and 1.7-fold (both P < .0001), respectively. Increased expression of nuclear or cytoplasmic AR-Ser(P)-213 was observed in metastatic breast cancers (1.3-fold, P = .05), ER-negative (2.6-fold, P = .001), and invasive ductal carcinoma (6.8-fold, P = .04). AR-Ser(P)-650 expression was downregulated in lymph node-positive breast cancers (1.4-fold, P = .02) but was upregulated in invasive ductal carcinomas (3.2-fold, P < .0001) and metastases (1.5-fold, P = .003). Moreover, in ER-negative breast cancers, nuclear AR-Ser(P)-650 was decreased (1.4-fold, P = .005), and cytoplasmic AR-Ser(P)-650 was increased (1.4-fold, P = .003). CONCLUSIONS: AR and its phosphorylation at serines 213 and 650 are differentially expressed in breast cancer tumorigenesis and progression. Phosphorylation of AR at serines 213 and 650 is increased in ER-negative breast cancers, ductal carcinomas, and metastases and may have predictive value in breast cancer prognosis.
BACKGROUND:Androgen receptor (AR) expression in breast cancers may serve as a prognostic and predictive marker. We examined the expression pattern of AR and its phosphorylated forms, Ser-213 (AR-Ser[P]-213) and Ser-650 (AR-Ser[P]-650), in breast cancer and evaluated their association with clinicopathological parameters. METHODS: Immunohistochemistry was performed on primary and distant metastatic breast cancers and benign breast tissue using antibodies against AR, AR-Ser(P)-213, and AR-Ser(P)-650. The levels of cytoplasmic and nuclear expression were scored semiquantitatively using a histoscore. RESULTS: Nuclear staining of AR was observed in all benign breast tissue and 67% of cancer cases. Nuclear and cytoplasmic AR-Ser(P)-213 was increased in breast cancers 2-fold (P = .0014) and 1.7-fold (P = .05), respectively, compared with benign controls, whereas nuclear and cytoplasmic AR-Ser(P)-650 expression was decreased in tumors by 1.9-fold and 1.7-fold (both P < .0001), respectively. Increased expression of nuclear or cytoplasmic AR-Ser(P)-213 was observed in metastatic breast cancers (1.3-fold, P = .05), ER-negative (2.6-fold, P = .001), and invasive ductal carcinoma (6.8-fold, P = .04). AR-Ser(P)-650 expression was downregulated in lymph node-positive breast cancers (1.4-fold, P = .02) but was upregulated in invasive ductal carcinomas (3.2-fold, P < .0001) and metastases (1.5-fold, P = .003). Moreover, in ER-negative breast cancers, nuclear AR-Ser(P)-650 was decreased (1.4-fold, P = .005), and cytoplasmic AR-Ser(P)-650 was increased (1.4-fold, P = .003). CONCLUSIONS:AR and its phosphorylation at serines 213 and 650 are differentially expressed in breast cancer tumorigenesis and progression. Phosphorylation of AR at serines 213 and 650 is increased in ER-negative breast cancers, ductal carcinomas, and metastases and may have predictive value in breast cancer prognosis.
Authors: Min Ni; Yiwen Chen; Elgene Lim; Hallie Wimberly; Shannon T Bailey; Yuuki Imai; David L Rimm; X Shirley Liu; Myles Brown Journal: Cancer Cell Date: 2011-07-12 Impact factor: 31.743
Authors: Ben E Black; Michael J Vitto; Daniel Gioeli; Adam Spencer; Nima Afshar; Mark R Conaway; Michael J Weber; Bryce M Paschal Journal: Mol Endocrinol Date: 2003-12-18
Authors: Francesca De Amicis; Janagi Thirugnansampanthan; Yukun Cui; Jennifer Selever; Amanda Beyer; Irma Parra; Nancy L Weigel; Matthew H Herynk; Anna Tsimelzon; Michael T Lewis; Gary C Chamness; Susan G Hilsenbeck; Sebastiano Andò; Suzanne A W Fuqua Journal: Breast Cancer Res Treat Date: 2009-06-17 Impact factor: 4.872
Authors: Amelia A Peters; Grant Buchanan; Carmela Ricciardelli; Tina Bianco-Miotto; Margaret M Centenera; Jonathan M Harris; Shalini Jindal; Davendra Segara; Li Jia; Nicole L Moore; Susan M Henshall; Stephen N Birrell; Gerhard A Coetzee; Robert L Sutherland; Lisa M Butler; Wayne D Tilley Journal: Cancer Res Date: 2009-07-28 Impact factor: 12.701
Authors: Kate M Peters; Stacey L Edwards; Shalima S Nair; Juliet D French; Peter J Bailey; Kathryn Salkield; Sandra Stein; Sarah Wagner; Glenn D Francis; Susan J Clark; Melissa A Brown Journal: BMC Cancer Date: 2012-04-02 Impact factor: 4.430
Authors: Valerie N Barton; Nicholas C D'Amato; Michael A Gordon; Hanne T Lind; Nicole S Spoelstra; Beatrice L Babbs; Richard E Heinz; Anthony Elias; Paul Jedlicka; Britta M Jacobsen; Jennifer K Richer Journal: Mol Cancer Ther Date: 2015-02-23 Impact factor: 6.261
Authors: Roshan Sriram; Vivian Lo; Benjamin Pryce; Lilia Antonova; Alan J Mears; Manijeh Daneshmand; Bruce McKay; Simon J Conway; William J Muller; Luc A Sabourin Journal: Breast Cancer Res Date: 2015-01-16 Impact factor: 6.466
Authors: Suthat Chottanapund; M B M Van Duursen; Kumpol Ratchaworapong; Panida Navasumrit; Mathuros Ruchirawat; Martin Van den Berg Journal: Med Sci (Basel) Date: 2016-09-14